INSYS reiterates commitment to ethical practices after indictment of five docs tied to the company

|By:, SA News Editor

INSYS Therapeutics (NASDAQ:INSY) is down 5% premarket, albeit on only 8 shares, on the heels of its statement that it remains committed to ethical behavior and the resolution of past issues related to its promotion of pain med Subsys (fentanyl).

The company responded after the feds indicted five New York physicians last week with ties to former employees.

Subscribe for full text news in your inbox